Illumina Inc (ILMN) 198.54 $ILMN
Is This Company the Big Winner in Obama's Push for Precision Medicine?
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 9 mins ago
Source: Illumina Inc. President Obama has released more details about his plans to fund a precision medicine initiative that the administration hopes will mean that doctors can deliver the right medicine to the right patient at the right dose ...
JNJ: 99.62 (+1.18), BMRN: 100.76 (+1.98), AZN: 69.96 (+0.20), ILMN: 198.54 (+1.81), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
Pacific Biosciences Is Being Eaten Alive By Illumina
Doug Van Cuyk - at Seeking Alpha - Thu Feb 12, 7:59AM CST
PACB: 6.96 (-0.06), ILMN: 198.54 (+1.81)
Healthcare stock screen of the month: Accelerating after-tax margins
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 11:21AM CST
MNK: 115.01 (+2.51), BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), BCR: 175.38 (+0.50), EVHC: 36.20 (-0.09), TMO: 127.61 (+0.78), CAH: 86.08 (+0.04), UTHR: 151.11 (+3.59), ILMN: 198.54 (+1.81), ACOR: 36.14 (-0.51), LCI: 57.78 (-0.91), JAZZ: 169.69 (+6.89), SHPG: 239.82 (+6.11), CPHD: 59.62 (+0.72), SYK: 94.51 (+1.14)
TrialReach Raises $13.5M Series B Led by Smedvig Capital
PR Newswire Europe - Thu Feb 05, 11:10AM CST
- Funding will fuel TrialReach's clinical trial platform growth and expansion into the U.S.
CSRE: 53.45 (-0.03), ILMN: 198.54 (+1.81)
Analysts View on Health Care Sector Equities -- GlaxoSmithKline, Novartis, Illumina, PerkinElmer, and Albany Molecular Research
PR Newswire - Thu Feb 05, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), Novartis AG (NYSE: NVS), Illumina Inc. (NASDAQ: ILMN), PerkinElmer Inc. (NYSE: PKI), and Albany Molecular Research Inc. (NASDAQ: AMRI). Free research report on GlaxoSmithKline can be accessed at http://get.Investor-Edge.com/pdf/?c=GlaxoSmit...&s=GSK. On Wednesday, February 04, 2015, the NASDAQ Composite ended at 4,716.70, down 0.23%, the Dow Jones Industrial Average advanced 0.04%, to finish the day at 17,673.02, and the S&P 500 closed at 2,041.51, down 0.42%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, while the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
ILMN: 198.54 (+1.81), GSK: 47.94 (+1.99), AMRI: 16.94 (-0.28), PKI: 46.30 (-0.10), NVS: 102.20 (-0.17)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Top Performing Funds Favor Leisure, Medical, REITs
at Investor's Business Daily - Tue Feb 03, 5:22PM CST
Amid falling oil prices and Greece's possible exit from the eurozone, the stock market started the first month of the year with volatility. The best-performing mutual funds the past three months slowed their buying in January. The outlook on IBD's...
AVIV: 36.45 (-0.08), BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), SPG: 193.11 (-1.61), PSA: 202.61 (-1.18), ILMN: 198.54 (+1.81), FRT: 143.96 (-0.58), JBLU: 16.83 (+0.09), EXR: 65.33 (-0.32), LUV: 43.30 (-0.20), CELG: 115.88 (+0.16), UAL: 66.23 (-1.11), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), SHPG: 239.82 (+6.11), PEB: 48.98 (-0.69), REG: 66.77 (-0.46), NLS: 15.38 (+0.12)
Illumina (ILMN) Stock Declines Today Despite Price Target Increase
at The Street - Tue Feb 03, 8:37AM CST
Illumina (ILMN) shares are falling despite a price target increase by analysts at Cantor Fitzgerald today.
ILMN: 198.54 (+1.81)
'Mad Money' Lightning Round: Don't Be Tempted by Southern Copper
at The Street - Tue Feb 03, 5:00AM CST
Cramer likes Illumina, does not like Atlas Energy and thinks Whirlpool is going to have a good earnings report this week.
WHR: 213.23 (+0.18), SCCO: 30.43 (+0.30), ATLS: 30.17 (+0.27), IP: 57.31 (+0.12), ILMN: 198.54 (+1.81), PKG: 82.89 (+1.86)
Many High Quality Stocks Are Down - Cramer's Lightning Round (2/2/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Feb 03, 4:50AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, February 2. Bullish Calls: Packaging Corporation Of America (NYSE: PKG ): "I like packaging, but I like International Paper (NYSE: IP )...
SCCO: 30.43 (+0.30), WHR: 213.23 (+0.18), GE: 25.15 (+0.26), ATLS: 30.17 (+0.27), IP: 57.31 (+0.12), ILMN: 198.54 (+1.81), PKG: 82.89 (+1.86)
Jim Cramer's 'Mad Money' Recap: New Month, New Rally in the Making?
at The Street - Mon Feb 02, 7:27PM CST
The markets were able to do something remarkable -- breaking the cycle of pain and ending the day higher after a weak open, Cramer says.
SCCO: 30.43 (+0.30), AMZN: 381.83 (+4.66), HAR: 136.40 (-3.18), AXP: 78.08 (-2.40), ATLS: 30.17 (+0.27), FB: 75.74 (-0.49), IP: 57.31 (+0.12), ILMN: 198.54 (+1.81), PKG: 82.89 (+1.86), WHR: 213.23 (+0.18), DXCM: 62.68 (+0.74), QCOM: 70.88 (+0.49), MSFT: 43.87 (+0.78), AAPL: 127.08 (+0.62), URI: 92.98 (+1.41)
Many Leading Stocks Stumble But Biogen, Harman Soar
at Investor's Business Daily - Fri Jan 30, 5:39PM CST
Many leading growth stocks stumbled as the market's uptrend came under pressure last week. But a few defied the turmoil. Investors reacted negatively to the Federal Reserve's statement on Wednesday; policymakers said that inflation was running below...
SBUX: 91.58 (-0.24), BIIB: 391.66 (-0.45), CAVM: 62.86 (-0.55), HAR: 136.40 (-3.18), ACT: 285.37 (+3.71), FB: 75.74 (-0.49), ILMN: 198.54 (+1.81), TSM: 24.84 (+0.37), ULTA: 136.66 (+0.59)
Top Earnings News: Illumina Back In Base Despite Beat
at Investor's Business Daily - Thu Jan 29, 5:03PM CST
Shares of Illumina sank back into a base after the company reported earnings, even though results topped expectations. The maker of gene-sequencing equipment initially jumped Wednesday, the day after Illumina (ILMN) announced. But the stock reversed...
ILMN: 198.54 (+1.81)
Insider Trading Alert - GME, SNI And ILMN Traded By Insiders
at The Street - Thu Jan 29, 10:08AM CST
Stocks with insider trader activity include GME, SNI and ILMN
GME: 37.35 (+0.10), ILMN: 198.54 (+1.81), SNI: 73.00 (+0.39)
How To Invest: Use Weekly Stock Charts Like A Pro
at Investor's Business Daily - Wed Jan 28, 4:31PM CST
The key unifying factor in stocks that make the IBD Spotlight screen is this: They are at or closing in on a 52-week high. This simple fact is crucial. To make money for those who bought properly, a superb growth stock must break out of a good base...
AMBA: 50.71 (-4.46), CSTE: 62.62 (+0.15), ILMN: 198.54 (+1.81)
Stocks Sell Off Into Close; Illumina, Yahoo Reverse Lower
at Investor's Business Daily - Wed Jan 28, 3:21PM CST
Stocks staged a big negative reversal Wednesday, selling off into the close. Selling intensified after the Fed's policy statement, despite no big surprises in the latest remarks. The Nasdaq reversed from an early 1.3% gain to finish down 0.9%. The...
YHOO: 44.42 (+0.50), ILMN: 198.54 (+1.81), NXPI: 84.79 (-0.60), AAPL: 127.08 (+0.62)
Stock Indexes Turn Mixed; Apple Stays Strong
at Investor's Business Daily - Wed Jan 28, 2:00PM CST
Stocks battled as they headed toward the last hour of trade Wednesday. The major indexes tumbled, turned mixed and remain stalled under their 50-day lines. The Nasdaq gripped an 0.1% gain after being up 1.3% just after the open. The S&P 500 fell...
HLT: 28.57 (+0.13), HD: 111.89 (-0.27), EA: 56.39 (+0.20), KNX: 32.26 (+0.88), ORLY: 205.55 (-1.02), ILMN: 198.54 (+1.81), BA: 149.73 (+1.64), AAPL: 127.08 (+0.62), BABA: 89.05 (+1.95)
Illumina Q4 Results Trigger Price Target Increases
at Investor's Business Daily - Wed Jan 28, 1:35PM CST
Wedbush Securities and Maxim Group raised Illumina's (ILMN) price targets a day after the maker of gene-sequencing systems reported fourth-quarter earnings that beat analysts' views on a huge rise in EPS. Wedbush noted in a Jan. 28 post-earnings...
ILMN: 198.54 (+1.81)
Nasdaq Recovers After Reversal; Apple Shines Brightly
at Investor's Business Daily - Wed Jan 28, 12:32PM CST
The Nasdaq reversed a better-than-1% gain early Wednesday but recovered a bit in early afternoon trading. Techs got a boost early after Apple (AAPL) reported strong earnings late Tuesday. The Nasdaq added 0.5%, the Dow Jones industrial average gained...
SSNC: 63.38 (+1.40), FB: 75.74 (-0.49), ILMN: 198.54 (+1.81), ADVS: 44.18 (+0.20), AAPL: 127.08 (+0.62), PAYC: 32.37 (-0.71)
Is This Company the Big Winner in Obama's Push for Precision Medicine?
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 9 mins ago
Source: Illumina Inc. President Obama has released more details about his plans to fund a precision medicine initiative that the administration hopes will mean that doctors can deliver the right medicine to the right patient at the right dose ...
JNJ: 99.62 (+1.18), BMRN: 100.76 (+1.98), AZN: 69.96 (+0.20), ILMN: 198.54 (+1.81), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
Pacific Biosciences Is Being Eaten Alive By Illumina
Doug Van Cuyk - at Seeking Alpha - Thu Feb 12, 7:59AM CST
PACB: 6.96 (-0.06), ILMN: 198.54 (+1.81)
Healthcare stock screen of the month: Accelerating after-tax margins
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 11:21AM CST
MNK: 115.01 (+2.51), BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), BCR: 175.38 (+0.50), EVHC: 36.20 (-0.09), TMO: 127.61 (+0.78), CAH: 86.08 (+0.04), UTHR: 151.11 (+3.59), ILMN: 198.54 (+1.81), ACOR: 36.14 (-0.51), LCI: 57.78 (-0.91), JAZZ: 169.69 (+6.89), SHPG: 239.82 (+6.11), CPHD: 59.62 (+0.72), SYK: 94.51 (+1.14)
TrialReach Raises $13.5M Series B Led by Smedvig Capital
PR Newswire Europe - Thu Feb 05, 11:10AM CST
- Funding will fuel TrialReach's clinical trial platform growth and expansion into the U.S.
CSRE: 53.45 (-0.03), ILMN: 198.54 (+1.81)
Analysts View on Health Care Sector Equities -- GlaxoSmithKline, Novartis, Illumina, PerkinElmer, and Albany Molecular Research
PR Newswire - Thu Feb 05, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), Novartis AG (NYSE: NVS), Illumina Inc. (NASDAQ: ILMN), PerkinElmer Inc. (NYSE: PKI), and Albany Molecular Research Inc. (NASDAQ: AMRI). Free research report on GlaxoSmithKline can be accessed at http://get.Investor-Edge.com/pdf/?c=GlaxoSmit...&s=GSK. On Wednesday, February 04, 2015, the NASDAQ Composite ended at 4,716.70, down 0.23%, the Dow Jones Industrial Average advanced 0.04%, to finish the day at 17,673.02, and the S&P 500 closed at 2,041.51, down 0.42%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, while the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.
ILMN: 198.54 (+1.81), GSK: 47.94 (+1.99), AMRI: 16.94 (-0.28), PKI: 46.30 (-0.10), NVS: 102.20 (-0.17)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Top Performing Funds Favor Leisure, Medical, REITs
at Investor's Business Daily - Tue Feb 03, 5:22PM CST
Amid falling oil prices and Greece's possible exit from the eurozone, the stock market started the first month of the year with volatility. The best-performing mutual funds the past three months slowed their buying in January. The outlook on IBD's...
AVIV: 36.45 (-0.08), BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), SPG: 193.11 (-1.61), PSA: 202.61 (-1.18), ILMN: 198.54 (+1.81), FRT: 143.96 (-0.58), JBLU: 16.83 (+0.09), EXR: 65.33 (-0.32), LUV: 43.30 (-0.20), CELG: 115.88 (+0.16), UAL: 66.23 (-1.11), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), SHPG: 239.82 (+6.11), PEB: 48.98 (-0.69), REG: 66.77 (-0.46), NLS: 15.38 (+0.12)
Illumina (ILMN) Stock Declines Today Despite Price Target Increase
at The Street - Tue Feb 03, 8:37AM CST
Illumina (ILMN) shares are falling despite a price target increase by analysts at Cantor Fitzgerald today.
ILMN: 198.54 (+1.81)
'Mad Money' Lightning Round: Don't Be Tempted by Southern Copper
at The Street - Tue Feb 03, 5:00AM CST
Cramer likes Illumina, does not like Atlas Energy and thinks Whirlpool is going to have a good earnings report this week.
WHR: 213.23 (+0.18), SCCO: 30.43 (+0.30), ATLS: 30.17 (+0.27), IP: 57.31 (+0.12), ILMN: 198.54 (+1.81), PKG: 82.89 (+1.86)
Many High Quality Stocks Are Down - Cramer's Lightning Round (2/2/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Feb 03, 4:50AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, February 2. Bullish Calls: Packaging Corporation Of America (NYSE: PKG ): "I like packaging, but I like International Paper (NYSE: IP )...
SCCO: 30.43 (+0.30), WHR: 213.23 (+0.18), GE: 25.15 (+0.26), ATLS: 30.17 (+0.27), IP: 57.31 (+0.12), ILMN: 198.54 (+1.81), PKG: 82.89 (+1.86)
Jim Cramer's 'Mad Money' Recap: New Month, New Rally in the Making?
at The Street - Mon Feb 02, 7:27PM CST
The markets were able to do something remarkable -- breaking the cycle of pain and ending the day higher after a weak open, Cramer says.
SCCO: 30.43 (+0.30), AMZN: 381.83 (+4.66), HAR: 136.40 (-3.18), AXP: 78.08 (-2.40), ATLS: 30.17 (+0.27), FB: 75.74 (-0.49), IP: 57.31 (+0.12), ILMN: 198.54 (+1.81), PKG: 82.89 (+1.86), WHR: 213.23 (+0.18), DXCM: 62.68 (+0.74), QCOM: 70.88 (+0.49), MSFT: 43.87 (+0.78), AAPL: 127.08 (+0.62), URI: 92.98 (+1.41)
Many Leading Stocks Stumble But Biogen, Harman Soar
at Investor's Business Daily - Fri Jan 30, 5:39PM CST
Many leading growth stocks stumbled as the market's uptrend came under pressure last week. But a few defied the turmoil. Investors reacted negatively to the Federal Reserve's statement on Wednesday; policymakers said that inflation was running below...
SBUX: 91.58 (-0.24), BIIB: 391.66 (-0.45), CAVM: 62.86 (-0.55), HAR: 136.40 (-3.18), ACT: 285.37 (+3.71), FB: 75.74 (-0.49), ILMN: 198.54 (+1.81), TSM: 24.84 (+0.37), ULTA: 136.66 (+0.59)
Top Earnings News: Illumina Back In Base Despite Beat
at Investor's Business Daily - Thu Jan 29, 5:03PM CST
Shares of Illumina sank back into a base after the company reported earnings, even though results topped expectations. The maker of gene-sequencing equipment initially jumped Wednesday, the day after Illumina (ILMN) announced. But the stock reversed...
ILMN: 198.54 (+1.81)
Insider Trading Alert - GME, SNI And ILMN Traded By Insiders
at The Street - Thu Jan 29, 10:08AM CST
Stocks with insider trader activity include GME, SNI and ILMN
GME: 37.35 (+0.10), ILMN: 198.54 (+1.81), SNI: 73.00 (+0.39)
How To Invest: Use Weekly Stock Charts Like A Pro
at Investor's Business Daily - Wed Jan 28, 4:31PM CST
The key unifying factor in stocks that make the IBD Spotlight screen is this: They are at or closing in on a 52-week high. This simple fact is crucial. To make money for those who bought properly, a superb growth stock must break out of a good base...
AMBA: 50.71 (-4.46), CSTE: 62.62 (+0.15), ILMN: 198.54 (+1.81)
Stocks Sell Off Into Close; Illumina, Yahoo Reverse Lower
at Investor's Business Daily - Wed Jan 28, 3:21PM CST
Stocks staged a big negative reversal Wednesday, selling off into the close. Selling intensified after the Fed's policy statement, despite no big surprises in the latest remarks. The Nasdaq reversed from an early 1.3% gain to finish down 0.9%. The...
YHOO: 44.42 (+0.50), ILMN: 198.54 (+1.81), NXPI: 84.79 (-0.60), AAPL: 127.08 (+0.62)
Stock Indexes Turn Mixed; Apple Stays Strong
at Investor's Business Daily - Wed Jan 28, 2:00PM CST
Stocks battled as they headed toward the last hour of trade Wednesday. The major indexes tumbled, turned mixed and remain stalled under their 50-day lines. The Nasdaq gripped an 0.1% gain after being up 1.3% just after the open. The S&P 500 fell...
HLT: 28.57 (+0.13), HD: 111.89 (-0.27), EA: 56.39 (+0.20), KNX: 32.26 (+0.88), ORLY: 205.55 (-1.02), ILMN: 198.54 (+1.81), BA: 149.73 (+1.64), AAPL: 127.08 (+0.62), BABA: 89.05 (+1.95)
Illumina Q4 Results Trigger Price Target Increases
at Investor's Business Daily - Wed Jan 28, 1:35PM CST
Wedbush Securities and Maxim Group raised Illumina's (ILMN) price targets a day after the maker of gene-sequencing systems reported fourth-quarter earnings that beat analysts' views on a huge rise in EPS. Wedbush noted in a Jan. 28 post-earnings...
ILMN: 198.54 (+1.81)
Nasdaq Recovers After Reversal; Apple Shines Brightly
at Investor's Business Daily - Wed Jan 28, 12:32PM CST
The Nasdaq reversed a better-than-1% gain early Wednesday but recovered a bit in early afternoon trading. Techs got a boost early after Apple (AAPL) reported strong earnings late Tuesday. The Nasdaq added 0.5%, the Dow Jones industrial average gained...
SSNC: 63.38 (+1.40), FB: 75.74 (-0.49), ILMN: 198.54 (+1.81), ADVS: 44.18 (+0.20), AAPL: 127.08 (+0.62), PAYC: 32.37 (-0.71)
